“Feedback of the first phase of Iranian coronavirus human trial was satisfactory and it has caused no side effect so far,” he told reporters.
“Two to three million doses of vaccines will be produced in Iran by the end of the current Iranian year,” Mokhber added.
He stated that the first phase of the human trial phase is about to finish.
“The vaccine will be available to the public next Iranian year,” Mokhber noted.
End Item
Follow us on Twitter @Isna_Int
Comments